



Editorial

Is the Blood Eosinophil Count a Useful Biomarker in COPD? The devil is in the Details!



¿Es el recuento de eosinófilos un biomarcador útil en la EPOC? El problema está en los detalles

Bartolome Celli

Harvard University, Boston, United States

Eosinophils are pleiotropic leukocytes with multiple biological functions.¹ They participate in the initiation and propagation of diverse inflammatory responses, and also modulate adaptive immunity by directly activating T cells. They are derived from bone marrow, and most usually reside in the gastrointestinal tract. The lung is not their natural environment, and their presence in that organ is indicative of an abnormal inflammatory response. Thus, it is entirely logical that increased eosinophil levels in expectorated sputum, bronchoalveolar lavage and/or tissue biopsy have been used to define the presence of pathological processes capable of resulting in disease states, such as asthma, eosinophilic pulmonary syndromes, and certain autoimmune and neoplastic diseases. Many of these pathologies are associated with an increase in peripheral blood eosinophil levels. Pathological eosinophil levels are determined using absolute counts, with mild eosinophilia being defined as 351–500 cells/mm³, moderate eosinophilia as 500–1500 cells/mm³, and severe eosinophilia as more than 1500 cells/mm³. To establish a diagnosis of hyper-eosinophilia, pathological levels must persist for a number of months.² This is an important consideration when interpreting elevated eosinophilic blood count in a particular patient. Finally, blood eosinophil levels are often reported as a proportion of the total number of leukocytes, with values ranging from 1% to 6%.

In COPD, there is widespread consensus on the need for biomarkers that can identify treatable features that can be targeted by specific therapies. In this disease, serum eosinophil level have a good correlation with sputum eosinophils,³ and are certainly more easily measured. Recent evidence has highlighted the potential use of sputum and serum eosinophil levels as biomarkers of patients likely to suffer from exacerbations and to respond to corticosteroids or other anti-eosinophilic therapies.^{4–6} These drugs have been shown to be effective in reducing eosinophil levels and the clinical manifestations of eosinophilic diseases; by and large, the higher the eosinophil count the more effective the therapy. What, then, is the evidence in COPD?

Overall, a retrospective analysis of data obtained in clinical trials suggests an increased rate of exacerbations in patients with blood eosinophilia. Pascoe et al.⁷ reviewed the data from 3177 patients with COPD and a previous history of exacerbations treated with either once daily ICS/LABA (Fluticasone/Vilanterol) or LABA (Vilanterol) alone, with 2083 patients (66%) with an eosinophil count of 2% or higher at study entry. All doses of ICS reduced exacerbations by 29% compared with LABA alone (mean 0.91 vs 1.28 exacerbations per patient per year; $P < .0001$) in patients with eosinophil counts of 2% or higher, and by 10% (0.79 vs 0.89; $P = .2827$) in patients with eosinophil counts lower than 2%. Reductions in exacerbations with ICS/LABA compared with LABA alone were 24% in patients with baseline eosinophil counts of ≥ 2 to $< 4\%$, 32% for those with counts of 4 to $< 6\%$, and 42% for those with eosinophil counts of $\geq 6\%$. Siddiqui et al.⁸ observed a similar effect using a different combination of twice daily ICS/LABA (beclomethasone/formoterol) versus LABA alone. In this study, patients in the highest quartile of eosinophil count (> 281 cell/mm³) had the greatest benefit both in exacerbation rate as well as health status. Combining the data from three studies using yet another twice daily ICS/LABA combination (fluticasone/salmeterol) compared with LABA alone, Pavord et al.⁹ observed a decrease in exacerbation rate, with no impact on lung function decline or health status in 2 of the 3 studies using the 2% threshold. The number of studies supporting such a relationship has increased, with some showing an association between eosinophil levels and improvement in lung function¹⁰ decline, while others confirm the relationship with exacerbations.¹¹

Although most clinicians and investigators associate the presence of exacerbations with poor outcomes, this cannot be extrapolated to a similar association between eosinophilia and poor outcomes. Indeed, a review of the results of the ISOLDE study showed that administration of ICS was associated with a slower rate of lung function decline in patients with higher versus lower serum eosinophil levels.¹⁰ In a study of the relationship between eosinophil levels and clinical characteristics in a US population-based cohort, eosinophil $> 2\%$ was associated with fewer

E-mail address: BCelli@copdnet.org

co-morbidities.¹² Further, in a recent cohort study of patients with COPD, the presence of eosinophilia was associated with a lower risk of death over 10 years of follow-up.¹³

Overall, interpretation of the data available seems to point to a relationship between eosinophil levels and COPD exacerbations. As is true in eosinophilic diseases, the administration of corticosteroids (or perhaps other immunomodulators) seem to have a beneficial effect on exacerbations in patients with a history of exacerbation and eosinophilia. However, many unanswered questions remain:

1. Is the widely suggested 2% white blood cell cut-off level the right threshold? That value is within normal limits. Indeed, when applied to the general population, this threshold was surpassed in 65% of healthy individuals and 70% of patients with COPD, respectively.
2. Is a single serum eosinophilia measurement sufficient to identify susceptibility phenotypes? There is little information about the stability of serum eosinophil levels over time in COPD.
3. Is the evidence solid enough to warrant a change in clinical practice? So far, no studies in COPD have prospectively evaluated the effect of any particular therapy using blood eosinophils thresholds as an inclusion criterion.
4. Is the eosinophil a friend or a foe? The relationship between eosinophil levels and outcomes other than exacerbations is not known. Whether suppression of eosinophil levels that fall within the normal ranges in the general population carries a risk remains to be seen.

In conclusion, these are exciting times. The possibility that an easily obtained biomarker such as peripheral blood eosinophil count may help determine a patient's risk for certain outcomes and likelihood of responding to specific therapy is very appealing. However, as in many areas in life, "the devil is in the details", and more data is needed before blood eosinophil levels can be used to identify a COPD phenotype amenable to specific immunomodulatory therapy.

References

1. Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, et al. Eosinophils biological properties and role in health and disease. *Clin Exp Allergy: J Br Soc Allergy Clin Immunol*. 2008;38:709–50.
2. Klion AD, Bochner BS, Gleich GJ, Nutman TB, Rothenberg ME, Simon HU, et al., The Hypereosinophilic Syndromes Working G. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. *J Allergy Clin Immunol*. 2006;117:1292–302.
3. Negewo NA, McDonald VM, Baines KJ, Wark PA, Simpson JL, Jones PW, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. *Int J Chron Obstruct Pulmon Dis*. 2016;11:1495–504.
4. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. *Am J Respir Crit Care Med*. 2011;184:662–71.
5. Eltboli O, Brightling CE. Eosinophils as diagnostic tools in chronic lung disease. *Expert Rev Respir Med*. 2013;7:33–42.
6. Balotra Villar A, Pallares Sanmartin A. Chronic obstructive pulmonary disease with eosinophilia, an emerging phenotype? *Arch Bronconeumol*. 2016;52:177–8.
7. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials. *Lancet Resp Med*. 2015;3:435–42.
8. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2015;192:523–5.
9. Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. *Thorax*. 2016;71:118–25.
10. Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. *Eur Respir J*. 2016;47:1374–82.
11. Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the Wisdom trial. *Lancet Resp Med*. 2016;4:390–8.
12. DiSantostefano RL, Hinds D, Le HV, Barnes NC. Relationship between blood eosinophils and clinical characteristics in a cross-sectional study of a us population-based COPD cohort. *Respir Med*. 2016;112:88–96.
13. Suzuki M, Makita H, Konno S, Shimizu K, Kimura H, Kimura H, et al. Asthma-like features and clinical course of COPD: an analysis from the hokkaido COPD cohort study. *Am J Respir Crit Care Med*. 2016.